ViewRay Inc. began a phase III randomized controlled trial titled “Locally Advanced Pancreatic cancer treated with ABLATivE stereotactic MRI-guided adaptive radiation therapy”—also known as LAP-ABLATE—which will compare stand-alone multi-agent chemotherapy, which is the current standard of care for patients with locally advanced pancreatic cancer, to patients receiving a combination of chemotherapy and 5-fraction MRIdian stereotactic MR-guided adaptive radiotherapy.
Feng Yang’s lab at Baylor College of Medicine published a study in the Proceedings of the National Academy of Sciences, which looked into what drives the growth of advanced tumors that have become resistant to standard castration therapy. Working with cells in the lab and animal models, they discovered an approach that suppresses the growth of therapy-resistant tumors.
Scott Verbridge, associate professor in biomedical engineering and mechanics at Virginia Tech, and Barath Udayasuryan, an alumnus from the Virginia Tech-Wake Forest University School of Biomedical Engineering and Sciences, have discovered a characteristic of a common oral bacterium that relocates to pancreatic cancer tumors which may help guide future therapeutic interventions for treatment.
New research indicates that among individuals with breast cancer, those with a rare subtype called inflammatory breast cancer face a higher risk that their cancer will metastasize to the brain.
Allogene Therapeutics Inc., a clinical-stage biotechnology company, has initiated the first phase II clinical trial of allogeneic CAR T-cell therapy.
Female cancer patients are less satisfied with the quality of their cancer care than male cancer patients, and are more likely to report that their symptoms were not taken seriously and that they had to prove their symptoms to providers.
In a research paper published in PLOS ONE, Dario C. Altieri, president and chief executive officer, director of the Ellen and Ronald Caplan Cancer Center, and the Robert and Penny Fox Distinguished Professor at The Wistar Institute, alongside national and international collaborators, distinguish a specific gene signature indicative of mitochondrial reprogramming in tumors that correlates with poor patient outcome.
The PERLA phase II trial met its primary endpoint of objective response rate by Response Evaluation Criteria in Solid Tumors criteria as determined by blinded independent central review. The trial evaluated Jemperli (dostarlimab) in combination with chemotherapy versus pembrolizumab in combination with chemotherapy in first-line patients with metastatic non-squamous NSCLC.
Researchers at UNC Lineberger Comprehensive Cancer Center have found a possible way to overcome barriers that block effective anti-cancer immune responses, thereby opening the potential for more effective immunotherapies in people.
A collaborative effort between investigators at Roswell Park Comprehensive Cancer Center and the Center for Molecular Immunology in Havana, Cuba, has revealed a new strategy for correcting immune dysfunction in cancer patients.
